NCT07649005 Interactive Effects of Sodium and Potassium on Vascular Health in Older Adults
| NCT ID | NCT07649005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida State University |
| Condition | Healthy Older Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-24 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-03-24 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine if a high potassium intake can counteract the harmful effects of excess sodium on endothelial function in older adults with no history of cardiometabolic disease. The main questions it aims to answer are: 1. Can a high potassium intake attenuate dietary sodium-induced endothelial dysfunction in older adults. 2. Do changes in endothelial function in response to alterations in sodium and potassium intake differ by sex. Participants will participants will consume three controlled diets for 10 days each with a minimum 14-day washout between interventions. The order in which participants consume the diets will be randomized. The study diets will vary in sodium and potassium content. Measures of cardiovascular health (blood pressure, arterial stiffness, endothelial function) will be assessed at the end of each diet.
Eligibility Criteria
Inclusion Criteria: * Adults ages 55-75 years * At least one-year post-menopause (females) * Willing and able to attend laboratory visits Exclusion Criteria: * BMI ≥35 kg/m2 * Seated blood pressure \>135/85 mmHg * Current diagnosis or history of cardiovascular disease, diabetes, renal disease, cancer, or major cardiovascular event (e.g. heart attack or stroke) * Taking exogenous hormones or hormone replacement therapy * Following a vegan or gluten free diet * Significant weight loss (\>10% of body weight) in the last 6 months, or actively trying to lose weight * Current or recent use of a diuretic (within the past 6 months) (e.g. spironolactone, eplerenone) * Current or recent use of a potassium binding medication (within the past 6 months) * Current use of blood pressure lowering medications (e.g. ACE inhibitors, calcium channel blockers, diuretics, vasodilators, beta blockers, AngII receptor blockers) * Current or recent use of the medication trimethoprim * Elevated blood lipids (LDL cholesterol ≥190 mg/dL) * Elevated serum potassium level (\>5.1 mmol/L) * Elevated BUN (\>22 mg/dL) * Elevated creatinine (\>1.2 mg/dL) * Low eGFR (\<90 mL/min/1.73 m²) * Current or recent use of tobacco, nicotine, or illicit drugs * Radical hysterectomy or oophorectomy (females)
Contact & Investigator
Andrea Lobene
PRINCIPAL INVESTIGATOR
Florida State University
Frequently Asked Questions
Who can join the NCT07649005 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 75 Years, studying Healthy Older Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07649005 currently recruiting?
Yes, NCT07649005 is actively recruiting participants. Contact the research team at alobene@fsu.edu for enrollment information.
Where is the NCT07649005 trial being conducted?
This trial is being conducted at Tallahassee, United States.
Who is sponsoring the NCT07649005 clinical trial?
NCT07649005 is sponsored by Florida State University. The principal investigator is Andrea Lobene at Florida State University. The trial plans to enroll 30 participants.